Join the club for FREE to access the whole archive and other member benefits.

Radical new cancer treatment to be trialled next year

24-Nov-2017

Key points from article :

Uses cancer-killing cells from people with the strongest immune systems.

Neutrophil cells form part of the body’s first line of defence.

Multiplied millions of times and injected into cancer patients.

Initially focusing on pancreatic cancer.

Hope to see patients experiencing complete remission

Mentioned in this article:

Click on resource name for more details.

Alex Blyth

Founder and Chief Executive Officer of LIfT BioSciences.

Farzin Farzaneh

Professor of Molecular Medicine at King's College London.

King’s College London

Public research university

LIfT BioSciences

Biotechnology company that develops a portfolio of potentially life-saving immuno-oncology cell therapies

Topics mentioned on this page:
Cancer